ADVA
23.11.2021 09:02:05 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that KCOM is harnessing its FSP 3000 open optical transport technology to meet soaring data demand. The new infrastructure enables the UK-based communication and IT service provider to deliver highly reliable, ultra-fast connectivity to more residential and business customers across the Yorkshire and North Lincolnshire regions. Featuring ADVA’s QuadFlex™ line card, OpenFabric™ cross-connect and colorless, directionless, flexgrid ROADM technology, the solution empowers KCOM to remotely turn up new services with complete flexibility and control. After managing all stages of design, implementation, optimization and testing, ADVA’s specialist team will provide ongoing maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005140/en/
“Last year, we deployed ADVA’s packet edge technology as we created the UK’s first full-fiber city. Through that process, we built up a great relationship with the ADVA team. So, when it came to taking our optical network to the next level, it made sense to turn to a partner whom we can rely on, who shares our ambitions and who we know will support us every step of the way,” said Tim Shaw, managing director, KCOM Wholesale and Networks. “With ADVA handling all elements of planning, project management and maintenance, we can concentrate on doing what we do best. Our new transport infrastructure will be a key tool in helping us deliver world-class fiber broadband to even more customers. It’s going to give households and businesses across the region a major boost.”
Designed for scale, bandwidth optimization and low-power consumption, the ADVA FSP 3000 platform ensures that KCOM’s new transport system provides superb efficiency. Using ADVA FSP 3000 QuadFlex™ technology, the solution will transport 100Gbit/s data loads across the region without the need for signal regeneration. Also key is the ADVA FSP 3000 OpenFabric™ , which enables easy aggregation of lower-speed services. What’s more, KCOM is also utilizing ADVA’s comprehensive portfolio of professional services to accelerate deployment and then maintain efficiency and service quality. The partnership guarantees that customers receive a network specifically tailored to their exact business requirements and backed up by 24/7 technical support.
“The new solution is highly reliable, fully flexible and extremely cost-efficient. And thanks to the modular, scalable design of our FSP 3000 platform, KCOM can plan an exciting roadmap for further expansion and development in the future,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “We’re proud to be KCOM’s technology partner, enhancing all aspects of network rollout and maintenance and helping to expand the horizons of KCOM’s business. Our highly experienced engineers and consultants ensure speed, efficiency and overall quality, freeing KCOM to focus on new revenue opportunities and empowering its growing numbers of enterprise customers throughout Yorkshire and North Lincolnshire to do the same.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005140/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom